Related Experiment Video
Updated: Jun 26, 2026
06:46
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Type 1 Diabetes TrialNet--an international collaborative clinical trials network
Jay S Skyler1, Carla J Greenbaum, John M Lachin
1Diabetes Research Institute, Miami, Florida 33101-6960, USA. jskyler@miami.edu
Annals of the New York Academy of Sciences
|January 6, 2009
Summary
Type 1 Diabetes TrialNet researches ways to prevent or delay type 1 diabetes (T1D). Studies focus on immune modulation and beta cell regeneration to preserve function in at-risk individuals and those newly diagnosed.
Area of Science:
- Immunology
- Endocrinology
- Clinical Research
Background:
- Type 1 Diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic beta cells.
- Understanding the natural history of T1D is crucial for developing effective interventions.
- Identifying individuals at risk allows for early intervention and potential prevention strategies.
Purpose of the Study:
- To prevent or delay the onset of type 1 diabetes (T1D) through immune modulation and beta cell enhancement.
- To evaluate novel therapies for their risk/benefit profile in preserving beta cell function.
- To improve clinical trial methodologies, including outcome assessment and surrogate markers.
Main Methods:
- Conducting clinical trials focused on preventive measures for T1D.
- Evaluating therapies in individuals with newly diagnosed T1D and preserved beta cell function.
- Investigating the natural history of T1D and identifying at-risk populations.
Main Results:
- TrialNet actively recruits participants for prevention and treatment studies.
- Ongoing research aims to understand disease progression and identify therapeutic targets.
- Methodological studies are refining clinical trial conduct and evaluation.
Conclusions:
- Type 1 Diabetes TrialNet is dedicated to preventing or delaying T1D through innovative research.
- Clinical evaluation of novel therapies and improved trial methodologies are key to advancing T1D research.
- Understanding disease mechanisms and identifying at-risk individuals are central to TrialNet's mission.
Related Concept Videos
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...